DLA Piper Adds Life Sciences Patent Litigator Constance Lee As Partner In Washington, D.C.

DLA Piper has expanded its Intellectual Property and Technology practice with the addition of Constance (Connie) Lee as a partner in Washington, D.C. Lee brings experience handling patent and trade secret litigation, with a particular focus on biotechnology and other life sciences technologies.

Her appointment adds technical and litigation expertise to DLA Piper’s intellectual property practice as pharmaceutical and biotechnology businesses navigate disputes involving proprietary products, research, and commercialization rights.

Lee advises clients throughout the patent litigation process, beginning with pre-filing investigations and initial pleadings.

Her experience also includes fact and expert discovery, dispositive motions, trial preparation, and courtroom proceedings.

Her practice encompasses disputes involving patents and trade secrets, including matters arising under the Biologics Price Competition and Innovation Act and the Abbreviated New Drug Application framework.

These legal frameworks play important roles in pharmaceutical and biotechnology litigation, particularly when companies dispute the patent rights associated with biologic medicines or generic drug products.

Lee has represented clients in federal district courts and proceedings before the U.S. International Trade Commission and Patent Trial and Appeal Board.

Her experience also includes arbitration, providing additional capabilities for resolving disputes outside traditional court proceedings.

Before entering the legal profession, Lee spent seven years working as an engineer developing consumer-product packaging.

That technical background complements her legal practice by providing experience with engineering processes, product development, and the evaluation of technical information.

DLA Piper emphasized that combining litigation capabilities with advanced technical knowledge is important for representing clients in complex intellectual property disputes.

The firm’s patent litigation team works across technology-intensive industries, including pharmaceuticals, biotechnology, medical devices, telecommunications, semiconductors, electronics, automotive systems, and chemical engineering.

Lee’s arrival strengthens the life sciences component of that broader practice.

The appointment also follows two other additions to DLA Piper’s patent litigation leadership.

Robert Shaffer recently joined as Head of the Life Sciences Patent Litigation practice, bringing more than 25 years of experience handling significant patent disputes.

Sean Trainor also joined as Co-Head of the firm’s U.S. International Trade Commission practice.

Together, these appointments expand DLA Piper’s resources for clients managing intellectual property litigation across several forums.

The expansion reflects the growing importance of coordinated legal strategies for companies whose businesses depend on patented technologies and proprietary research.

In the life sciences industry, intellectual property disputes can influence product development, market entry, licensing strategies, and the commercialization of pharmaceutical innovations.

DLA Piper’s global Intellectual Property and Technology practice provides legal services involving patents, technology transactions, trade secrets, and related litigation.

Lee’s addition strengthens its Washington presence and provides additional experience for life sciences businesses facing complex patent disputes.

KEY QUOTE:

“Connie’s sophisticated life sciences patent litigation experience and deep technical background further strengthen our practice. Her perspective will be particularly valuable to life sciences companies navigating complex disputes involving their most important innovations.”

Erin Gibson, Global Lead Of DLA Piper’s Intellectual Property And Technology Practice